Previsioni

Il prezzo obiettivo medio degli analisti è +17,16€ (−54,60%). La mediana è +17,16€ (−54,60%).

Acquista	1
Mantieni	0
Vendi	0

Notizie Vai al feed delle notizie

Mind Medicine presents phase-3 strategy for MM120 after positive phase-2b data

Mind Medicine presented results and plans for MM120 at the TD Cowen Summit: the phase-2b study showed a significant 7.7-point improvement versus placebo after 12 weeks in generalized anxiety disorder, with a remission rate of 48% and a response rate of 65% in the 100-microgram group. The company has received Breakthrough Therapy designation from the FDA and plans a phase-3 program to assess long-term efficacy in GAD and to pursue MDD as an indication. Operationally, Mind Medicine intends to shorten monitoring times, test an ODT formulation, and optimize dosing and placebo management; adverse effects were mainly perceptual symptoms on the day of treatment. » Altro su de.investing.com
MindMed reports progress in phase 3 trials and solid financial position

MindMed is advancing the development of its phase 3 trials for novel therapies targeting generalized anxiety disorder and major depression, supported by $238 million in cash reserves. The company expects key trial results in 2026 and considers itself financially secure at least through 2027. Despite rising R&D expenses, MindMed remains optimistic about the market potential and regulatory approval of its drug candidates. » Altro su de.investing.com

Dati finanziari dell'azienda

Nell'ultimo trimestre, Mind Medicine (MindMed) ha registrato ricavi pari a 0,00€ e un utile netto di −139,31M€

(EUR)	giu 2026	YoY
Ricavi	0,00	-
Utile lordo	0,00	-
Utile netto	−139,31M	284,13%
EBITDA	−65,78M	91,89%

Dati fondamentali

Metrica	Valore
Capitalizzazione di mercato	+1,34Mld€
Numero di azioni	75,55M
Massimo/minimo a 52 settimane	+18,09€ - +4,03€
Dividendi	No
Beta	2,62
Rapporto P/E	−12,58
Rapporto PEG	+0,17
Rapporto P/B	+5,21
Rapporto P/S	0,00

Profilo aziendale

Mind Medicine (MindMed) Inc. ist ein biopharmazeutisches Unternehmen in der klinischen Phase und entwickelt neuartige Produkte zur Behandlung von Hirnleistungsstörungen in den Bereichen Psychiatrie, Sucht, Schmerz und Neurologie. Das Unternehmen entwickelt MM-120, das sich in Phase 2 zur Behandlung der generalisierten Angststörung und der Aufmerksamkeitsdefizit-Hyperaktivitätsstörung sowie zur Behandlung chronischer Schmerzen befindet, und MM-110, einen cholinergen a3ß4-Nicotinrezeptor-Antagonisten, der die Phase 1 zur Behandlung des Opioid-Entzugs abgeschlossen hat. Darüber hinaus entwickelt das Unternehmen MM-402, ein R-Enantiomer von 3,4-Methylendioxymethamphetamin für die Behandlung von Kernsymptomen der Autismus-Spektrum-Störung. Der Hauptsitz des Unternehmens befindet sich in Vancouver, Kanada.

Nome	Mind Medicine (MindMed)
CEO	Robert Barrow
Sede centrale	Vancouver, bc Canada
Sito web	mindmed.co
Settore	Sanità
Industria	Prodotti farmaceutici
Quotazione in borsa	15/11/2016
Dipendenti	74